Neurosterix, a spin-out company of Addex Therapeutics, has successfully completed Phase 1 clinical trials for NTX-253, a drug candidate targeting schizophrenia by modulating the muscarinic M4 receptor. The trials included both healthy volunteers and schizophrenia patients, providing important safety and pharmacokinetic data. With promising results, Neurosterix plans to move NTX-253 into Phase 2 clinical development to further evaluate its efficacy and safety. This progress highlights a significant step in developing new treatments for schizophrenia that may avoid side effects common with traditional therapies.
Neurosterix Phase 1 trials completion is the subject, providing context for health sector stocks on Pluang. As of Oct 08, 2026 12:11 WIB, 44 of 100 health stocks rose and 52 fell. Notable movers include AMWL at USD 12.72 (+3.67%), ABEO at USD 5.18 (+3.39%), and TDOC at USD 5.58 (-3.38%).
FLSmidth secured a DKK 360 million contract to supply advanced crushing and grinding equipment for a copper mine expansion in Northern Chile. The order includes the world's largest gyratory crusher, a large SAG mill, and three ball mills, with instal...
On October 8, 2026, Michelin repurchased 202,417 of its own ordinary shares at a weighted average price of €32.33 per share through over-the-counter transactions. The shares bought back are intended for cancellation, which can reduce the total number...
On October 8, 2026, Michelin executed a share buyback, purchasing 202,417 ordinary shares at a weighted average price of €32.33 per share. The shares were acquired through over-the-counter transactions involving several financial institutions and are...
FORVIA HELLA has secured two significant series orders for its EnergyCore solutions, including its first 3-in-1 high-voltage battery management system and a 48-volt PowerPack. These integrated systems reduce vehicle cost, complexity, weight, and spac...
Bavarian Nordic A/S has upgraded its financial outlook for 2026 due to stronger-than-expected sales in its Travel Health segment, particularly driven by increased demand for rabies vaccines in the U.S. amid rising rabies exposure. The company now exp...
